News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,836 Results
Type
Article (42624)
Company Profile (265)
Press Release (678938)
Multimedia
Podcasts (102)
Webinars (18)
Section
Business (206788)
Career Advice (2104)
Deals (35750)
Drug Delivery (114)
Drug Development (82390)
Employer Resources (174)
FDA (16599)
Job Trends (15198)
News (350418)
Policy (33696)
Tag
Academia (2636)
Accelerated approval (16)
Adcomms (26)
Allergies (116)
Alliances (50335)
ALS (137)
Alzheimer's disease (1589)
Antibody-drug conjugate (ADC) (206)
Approvals (16665)
Artificial intelligence (392)
Autoimmune disease (64)
Automation (25)
Bankruptcy (367)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (148)
Biotechnology (177)
Bladder cancer (120)
Brain cancer (45)
Breast cancer (459)
Cancer (3662)
Cardiovascular disease (308)
Career advice (1768)
Career pathing (35)
CAR-T (223)
CDC (46)
Cell therapy (602)
Cervical cancer (31)
Clinical research (68678)
Collaboration (1292)
Company closure (4)
Compensation (906)
Complete response letters (47)
COVID-19 (2737)
CRISPR (73)
C-suite (543)
Cystic fibrosis (126)
Data (4236)
Decentralized trials (2)
Denatured (24)
Depression (96)
Diabetes (437)
Diagnostics (6588)
Digital health (32)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (179)
Drug pricing (174)
Drug shortages (33)
Duchenne muscular dystrophy (194)
Earnings (89302)
Editorial (48)
Employer branding (22)
Employer resources (151)
Events (116430)
Executive appointments (926)
FDA (18955)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (13)
Funding (1167)
Gene editing (161)
Generative AI (30)
Gene therapy (488)
GLP-1 (967)
Government (4958)
Grass and pollen (6)
Guidances (336)
Healthcare (19202)
HIV (45)
Huntington's disease (35)
IgA nephropathy (52)
Immunology and inflammation (210)
Immuno-oncology (17)
Indications (52)
Infectious disease (2955)
Inflammatory bowel disease (172)
Inflation Reduction Act (13)
Influenza (88)
Intellectual property (181)
Interviews (339)
IPO (16691)
IRA (50)
Job creations (3792)
Job search strategy (1485)
Kidney cancer (13)
Labor market (69)
Layoffs (556)
Leadership (27)
Legal (8128)
Liver cancer (86)
Longevity (12)
Lung cancer (526)
Lymphoma (258)
Machine learning (28)
Management (59)
Manufacturing (583)
MASH (134)
Medical device (13794)
Medtech (13816)
Mergers & acquisitions (19910)
Metabolic disorders (1115)
Multiple sclerosis (134)
NASH (22)
Neurodegenerative disease (205)
Neuropsychiatric disorders (51)
Neuroscience (2549)
NextGen: Class of 2025 (6643)
Non-profit (4603)
Now hiring (57)
Obesity (545)
Opinion (256)
Ovarian cancer (126)
Pain (153)
Pancreatic cancer (161)
Parkinson's disease (229)
Partnered (27)
Patents (395)
Patient recruitment (297)
Peanut (54)
People (58790)
Pharmaceutical (64)
Pharmacy benefit managers (25)
Phase I (21338)
Phase II (30192)
Phase III (22579)
Pipeline (2639)
Policy (257)
Postmarket research (2618)
Preclinical (9111)
Press Release (67)
Prostate cancer (184)
Psychedelics (46)
Radiopharmaceuticals (259)
Rare diseases (600)
Real estate (6007)
Recruiting (69)
Regulatory (23950)
Reports (51)
Research institute (2398)
Resumes & cover letters (361)
Rett syndrome (15)
RNA editing (12)
RSV (65)
Schizophrenia (124)
Series A (190)
Series B (146)
Service/supplier (12)
Sickle cell disease (76)
Special edition (22)
Spinal muscular atrophy (153)
Sponsored (35)
Startups (3654)
State (2)
Stomach cancer (16)
Supply chain (96)
Tariffs (90)
The Weekly (76)
Vaccines (924)
Venture capital (62)
Weight loss (382)
Women's health (55)
Worklife (17)
Date
Last 7 days (509)
Last 30 days (2097)
Last 365 days (30762)
2025 (24122)
2024 (35612)
2023 (40444)
2022 (51623)
2021 (56260)
2020 (54757)
2019 (47414)
2018 (35723)
2017 (32581)
2016 (32089)
2015 (38127)
2014 (31806)
2013 (26776)
2012 (28973)
2011 (29659)
2010 (27723)
Location
Africa (762)
Alabama (71)
Alaska (7)
Arizona (270)
Arkansas (13)
Asia (39248)
Australia (6480)
California (9022)
Canada (2817)
China (828)
Colorado (381)
Connecticut (387)
Delaware (246)
Europe (84992)
Florida (1352)
Georgia (296)
Hawaii (2)
Idaho (62)
Illinois (711)
India (45)
Indiana (436)
Iowa (17)
Japan (305)
Kansas (119)
Kentucky (34)
Louisiana (16)
Maine (67)
Maryland (1195)
Massachusetts (6638)
Michigan (279)
Minnesota (525)
Mississippi (4)
Missouri (112)
Montana (29)
Nebraska (25)
Nevada (102)
New Hampshire (72)
New Jersey (2478)
New Mexico (28)
New York (2462)
North Carolina (1246)
North Dakota (9)
Northern California (4144)
Ohio (276)
Oklahoma (20)
Oregon (36)
Pennsylvania (1903)
Puerto Rico (18)
Rhode Island (43)
South America (1130)
South Carolina (47)
South Dakota (1)
Southern California (3480)
Tennessee (146)
Texas (1394)
United States (32880)
Utah (269)
Virginia (220)
Washington D.C. (78)
Washington State (757)
West Virginia (4)
Wisconsin (76)
Wyoming (1)
721,836 Results for "eli lilly canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
FDA’s Ad Crackdown Targets Novo, Lilly’s Oprah Special on GLP-1s
In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss drugs during a prime time special with Oprah Winfrey.
September 17, 2025
·
3 min read
·
Annalee Armstrong
Obesity
Lilly Paints ‘Competitive Profile’ for Obesity Pill With Detailed Late-Stage Data
The over-representation of males and Hispanic patients in Eli Lilly’s Phase III ATTAIN-1 study could explain why orforglipron “underperformed” expectations in a previous readout, according to analysts at BMO Capital Markets.
September 17, 2025
·
2 min read
·
Tristan Manalac
Diabetes
Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical significance in reducing major events such as cardiovascular death, heart attack and stroke.
July 31, 2025
·
2 min read
·
Heather McKenzie
Obesity
Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership
The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new small molecule obesity medications for Lilly.
August 14, 2025
·
1 min read
·
Dan Samorodnitsky
Manufacturing
Lilly to Bring Nearly 2,500 Jobs to Virginia With $5B Manufacturing Plant
This manufacturing site in Richmond, Virginia, is the first of four projects that Eli Lilly plans to reveal this year as part of a $27 billion U.S. investment announced earlier this year.
September 17, 2025
·
1 min read
·
Tristan Manalac
Obesity
Novo, Lilly Jostle For Market Lead in Obesity With New Regulatory Efforts
Both Novo Nordisk and Eli Lilly are eyeing regulatory advancements for their obesity blockbusters as the European Association for the Study of Diabetes’ annual conference continues this week.
September 16, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Marks Finds His Next Role as Lilly Snags Another Former FDA Regulator
Six months after his controversial departure from the top spot at the FDA’s biologics division, Peter Marks has landed at Eli Lilly, joining former colleague Rachael Anatol, who was ousted from the agency not long after Marks.
October 7, 2025
·
1 min read
·
Heather McKenzie
Obesity
Lilly Plots Path to FDA After Second Phase III Readout for Orforglipron
While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition,” they also pointed to a manufacturing advantage that could unlock a “double-digit billion dollar opportunity” for Eli Lilly.
August 26, 2025
·
2 min read
·
Tristan Manalac
Obesity
UPDATE: Lilly’s Oral Weight Loss Drug Underdelivers, But Executives See Real World Opportunity
Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ bear scenario for the oral med. Executives brushed off the concerns and said the drug will still have a wide advantage on the market.
August 7, 2025
·
4 min read
·
Annalee Armstrong
Legal
Texas Accuses Lilly of ‘Bribing’ Prescribers To Push Mounjaro, Zepbound in New Suit
Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.”
August 13, 2025
·
2 min read
·
Tristan Manalac
1 of 72,184
Next
